AIM ImmunoTech Inc has filed for a patent for its experimental drug Ampligen, a potential treatment for COVID-19-induced chronic fatigue. Ampligen is already approved for experimental treatments in other countries, and is currently being tested here in the US under an FDA authorized open-label expanded access treatment protocol to Chronic Fatigue Syndrome (CFS).
Charles Lapp, from the Hunter-Hopkins Center believes the drug could help the fatigue experienced by coronavirus patients. He said, “It is anticipated that COVID-19 will trigger a large number of CFS cases, providing an opportunity for the medical community to learn more about the onset and pathogenesis of CFS,” and “The investigational immune-modulating antiviral drug Ampligen might have a role to play in this scenario.”
CEO of the company, Thomas Equels said. “Given the large amount of clinical data already supporting Ampligen in Myalgic Encephalomyelitis/CFS we look forward to the chance to investigate how Ampligen may be of value should there be a surge of COVID-19 induced CFS-like cases worldwide.”